

Publications for Sarah Palmer

2018

Reeves, D., Duke, E., Wagner, T., Palmer, S., Spivak, A., Schiffer, J. (2018). A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation. *Nature Communications*, 9(1), 1-16. [More Information]

Hiener, B., Eden, J., Horsburgh, B., Palmer, S. (2018). Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing. *Journal of Visualized Experiments*, 140, 1-12. [More Information]

Winckelmann, A., Morcilla, V., Shao, W., Schleimann, M., Hojen, J., Schlub, T., Benton, P., Ostergaard, L., Sogaard, O., Tolstrup, M., Palmer, S. (2018). Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1 infected individuals. *AIDS*, 32(13), 1793-1802. [More Information]

Horsburgh, B., Palmer, S. (2018). Measuring HIV Persistence on Antiretroviral Therapy. *Advances in Experimental Medicine and Biology*, 1075, 265-284. [More Information]

Evans, V., van der Sluis, R., Solomon, A., Dantanarayana, A., McNeil, C., Garsia, R., Palmer, S., Fromentin, R., Chomont, N., Sekaly, R., et al (2018). Programmed cell death-1 (PD-1) contributes to the establishment and maintenance of HIV-1 latency. *AIDS*, 32(11), 1491-1497. [More Information]

Wang, X., Palmer, S. (2018). Single-molecule Techniques to Quantify and Genetically Characterise Persistent HIV. *Retrovirology*, 15(1), 3. [More Information]

Boyer, Z., Palmer, S. (2018). Targeting immune checkpoint molecules to eliminate latent HIV. *Frontiers in Immunology*, 9, 1-7. [More Information]

Rasmussen, T., McMahon, J., Chang, J., Audsley, J., Rhodes, A., Tennakoon, S., Dantanarayana, A., Spelman, T., Schmidt, T., Kent, S., Morcilla, V., Palmer, S., et al (2018). The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial. *The Lancet HIV*, 5(5), e221-e230. [More Information]

2017

Hiener, B., Horsburgh, B., Lee, E., Palmer, S. (2017). A20 The search for replication-competent HIV during effective therapy. *Virus Evolution*, 3(Suppl 1), 58. [More Information]

Hiener, B., Horsburgh, B., Eden, J., Barton, K., Schlub, T., Lee, E., van Stockenstrom, S., Odevall, L., Milush, J., Liegler, T., Palmer, S., et al (2017). Identification of Genetically Intact HIV-

1 Proviruses in Specific CD4+ T Cells from Effectively Treated Participants. *Cell Reports*, 21(3), 813-822. [More Information]

Rasmussen, T., McMahon, J., Chang, J., Symons, J., Roche, M., Dantanarayana, A., Okoye, A., Hiener, B., Palmer, S., Lee, W., et al (2017). Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome. *AIDS*, 31(13), 1839-1845. [More Information]

Koelsch, K., Rasmussen, T., Hey-Nguyen, W., Pearson, C., Xu, Y., Bailey, M., Marks, K., Sasson, S., Taylor, M., Tantau, R., Palmer, S., et al (2017). Impact of Allogeneic Hematopoietic Stem Cell Transplantation on the HIV Reservoir and Immune Response in 3 HIV-Infected Individuals. *JAIDS: Journal of Acquired Immune Deficiency Syndromes*, 75(3), 328-337. [More Information]

Winckelmann, A., Barton, K., Hiener, B., Shao, W., Ostergaard, L., Rasmussen, T., Sogaard, O., Tolstrup, M., Palmer, S. (2017). Peripheral blood cells contribute to HIV-1 viremia induced by romidepsin. *Virus Evolution*, 3(Suppl 1), S2-S2. [More Information]

Winckelmann, A., Barton, K., Hiener, B., Schlub, T., Shao, W., Rasmussen, T., Ostergaard, L., Sogaard, O., Tolstrup, M., Palmer, S. (2017). Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations. *AIDS*, 31(6), 771-779. [More Information]

Winckelmann, A., Barton, K., Hiener, B., Schlub, T., Shao, W., Rasmussen, T., Ostergaard, L., Sogaard, O., Tolstrup, M., Palmer, S. (2017). Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations. *AIDS*, 31(6), 771-779. [More Information]

2016

Lee, S., Bacchetti, P., Chomont, N., Fromentin, R., Lewin, S., O'Doherty, U., Palmer, S., Richman, D., Siliciano, J., Yukl, S., et al (2016). Anti-HIV antibody responses and the HIV reservoir size during antiretroviral therapy. *PLoS One*, 11(8), 1-13. [More Information]

Barton, K., Hiener, B., Winckelmann, A., Rasmussen, T., Shao, W., Byth Wilson, K., Lanfear, R., Solomon, A., McMahon, J., Harrington, S., Palmer, S., et al (2016). Broad activation of latent HIV-1 in vivo. *Nature Communications*, 7, 1-8. [More Information]

Barton, K., Winckelmann, A., Palmer, S. (2016). HIV-1 Reservoirs During Suppressive Therapy. *Trends in Microbiology*, 24(5), 345-355. [More Information]

<http://dx.doi.org/10.1016/j.tim.2016.01.006>>[More Information]

Barton, K., Palmer, S. (2016). How to Define the Latent Reservoir: Tools of the Trade. *Current HIV/AIDS Reports*, 13(2), 77-84. [More Information]

Deeks, S., Lewin, S., Ross, A., Ananworanich, J., Benkarine, M., Cannon, P., Chomont, N., Douek, D., Lifson, J., Palmer, S., et al (2016). International AIDS Society global scientific strategy: towards an HIV cure 2016. *Nature Medicine*, 22(8), 839-850. [More Information]

2015

Procopio, F., Fromentin, R., Kulpa, D., Brehm, J., Bebin, A., Strain, M., Richman, D., O'Doherty, U., Palmer, S., Hecht, F., et al (2015). A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals. *EBioMedicine*, 2(8), 872-881. [More Information]

Wightman, F., Solomon, A., Kumar, S., Urriola, N., Gallagher, K., Hiener, B., Palmer, S., Garsia, R., McNeil, C., Lewin, S. (2015). Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma. *AIDS*, 29(4), 504-506. [More Information]

Olesen, R., Vigano, S., Rasmussen, T., Sogaard, O., Ouyang, Z., Buzon, M., Bashirova, A., Carrington, M., Palmer, S., Brinkmann, C., et al (2015). Innate immune activity correlates with CD4 T cell-associated HIV-1 DNA decline during latency-reversing treatment with panobinostat. *Journal of Virology*, 89(20), 10176-10189. [More Information]

van Stockenstrom, S., Odevall, L., Lee, E., Sinclair, E., Bacchetti, P., Killian, M., Epling, L., Shao, W., Hoh, R., Ho, T., Palmer, S., et al (2015). Longitudinal Genetic Characterization Reveals That Cell Proliferation Maintains a Persistent HIV Type 1 DNA Pool During Effective HIV Therapy. *The Journal of Infectious Diseases*, 212(4), 596-607. [More Information]

2014

Markowitz, M., Evering, T., Garmon, D., Caskey, M., La Mar, M., Rodriguez, K., Sahi, V., Palmer, S., Prada, N., Mohri, H. (2014). A Randomized Open-Label Study of 3- Versus 5-Drug Combination Antiretroviral Therapy in Newly HIV-1 Infected Individuals. *JAIDS: Journal of Acquired Immune Deficiency Syndromes*, 66(2), 140-147. [More Information]

Elliott, J., Wightman, F., Solomon, A., Ghneim, K., Ahlers, J., Cameron, M., Smith, M., Spelman, T., McMahon, J., Velayudham, P., Palmer, S., et al (2014). Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy. *PLoS Pathogens*, 10(11), 1-19. [More Information]

Dahl, V., Gissle'n, M., Hagberg, L., Peterson, J., Shao, W., Spudich, S., Price, R., Palmer, S. (2014). An example of genetically distinct HIV type 1 variants in cerebrospinal fluid and plasma during suppressive therapy. *The Journal of*

Infectious Diseases, 209(10), 1618-1622. [More Information]

Cockerham, L., Siliciano, J., Sinclair, E., O'Doherty, U., Palmer, S., Yukl, S., Strain, M., Chomont, N., Hecht, F., Siliciano, R., et al (2014). CD4+ and CD8+ T Cell Activation Are Associated with HIV DNA in Resting CD4+ T Cells. *PLoS One*, 9(10), 1-8. [More Information]

Dahl, V., Peterson, J., Fuchs, D., Gisslen, M., Palmer, S., Price, R. (2014). Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. *AIDS*, 28(15), 2251-2258. [More Information]

Rasmussen, T., Tolstrup, M., Brinkmann, C., Olesen, R., Erikstrup, C., Solomon, A., Winckelmann, A., Palmer, S., Dinarello, C., Buzon, M., et al (2014). Panobinostat, a histone deacetylase inhibitor, for latent virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: A phase 1/2, single group, clinical trial. *The Lancet HIV*, 1(1), e13-e21. [More Information]

2013

Hatano, H., Yukl, S., Ferre, A., Graf, E., Somsouk, M., Sinclair, E., Abdel-Mohsen, M., Liegler, T., Harvill, K., Hoh, R., Palmer, S., et al (2013). Prospective Antiretroviral Treatment of Asymptomatic, HIV-1 Infected Controllers. *PLoS Pathogens*, 9(10), 1-13. [More Information]

Josefsson, L., Palmer, S., Faria, N., Lemey, P., Casazza, J., Ambrozak, D., Kearney, M., Shao, W., Kottlilil, S., Sneller, M., et al (2013). Single cell analysis of lymph node tissue from HIV-1 infected patients reveals that the majority of CD4+ T-cells contain one HIV-1 DNA molecule. *PLoS Pathogens*, 9(6), 1-12. [More Information]

Josefsson, L., von Stockenstrom, S., Faria, N., Sinclair, E., Bacchetti, P., Killian, M., Epling, L., Tan, A., Ho, T., Lemey, P., Palmer, S., et al (2013). The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. *Proceedings of the National Academy of Sciences of the United States of America*, 110(51), E4987-E4996. [More Information]

Hunt, P., Shulman, N., Hayes, T., Dahl, V., Somsouk, M., Funderburg, N., McLaughlin, B., Landay, A., Adeyemi, O., Gilman, L., Palmer, S., et al (2013). The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. *Blood*, 121(23), 4635-4646. [More Information]